Contact
Please use this form to send email to PR contact of this press release:
Proteostasis Therapeutics, Inc. Demonstrates Therapeutic Potential of a Proprietary Triple Combination Therapy for the Treatment of Cystic Fibrosis That Restores Activity of Mutant F508del CFTR Protein to 80% of Normal
TO: